APCAD
ANALYSIS OF PARENTAL CONTRIBUTION FOR ANEUPLOIDY DETECTION
At the Center for Medical Genetics at the UZ Brussel, we developed an innovative method called 'Analysis of Parental Contribution for Aneuploidy Detection' (APCAD). This computational method can be used to more accurately detect chromosome abnormalities in very early embryos. It is a key element in a new and improved version of preimplantation genetic testing for aneuploidy (PGT-A); PGT-A version 3.0. By applying the technique we aim to improve implantation rate and reduce the proportion of miscarriages during in vitro fertilization (IVF) treatments. In addition, it helps couples to gain insight in the genetic quality of the available embryos and their prognosis.
HIGHLIGHTS Most accurate diagnosis: our method outperforms standard sequencing techniques. Haploidy, triploidy, UPD and <<1Mb-sized deletions can be detected. Mitotic and meiotic chromosome abnormalities can be distinguished and mosaic abnormalities can be identified Limited samples required: compared to haplotyping techniques it has the advantage that only DNA from the couple is required. Relatives do not need to be contacted Prove the origin of the embryo: the method provides an additional barrier against gamete or embryo mix-up High potential for machine learning
CONTACT pick the best embryo
accurate diagnosis
prove embryo origin
●
●
VUB/UZ Brussel is actively looking for companies interested in licensing the patent pending APCAD technique for implementation in their platform
Academic staff: Pieter Verdyck pieter.verdyck@uzbrussel.be Frederik Hes frederik.hes@uzbrussel.be
●
●
Universitair Ziekenhuis Brussel Laarbeeklaan 101 1090 Jette
patent application